MYM V101

Drug Profile

MYM V101

Alternative Names: HIV gp41 vaccine - Mymetics; Mucosal HIV/AIDS vaccine - Mymetics; MYM-V101; MYM-V201; Second generation virosome-based HIV vaccine - Mymetics; Virosome-gp41 mucosal vaccine - Mymetics

Latest Information Update: 15 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mymetics Corporation
  • Developer Mymetics Corporation; Texas Biomedical Research Institute
  • Class AIDS vaccines; Antivirals
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - HIV infections

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 11 Apr 2016 Pharmacodynamic results from a preclinical trial in HIV infections released by Mymetics Corporation
  • 06 Apr 2016 Phase-I development is ongoing in Belgium
  • 09 Jul 2014 MYM V101 is available for licensing as of 28 Mar 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top